Welcome to our dedicated page for Wesana Health Holdings news (Ticker: WSNAF), a resource for investors and traders seeking the latest updates and insights on Wesana Health Holdings stock.
Wesana Health Holdings Inc. (WSNAF) has issued a series of news releases that trace its evolution from a data-driven life sciences company focused on mental health drug development and care delivery to a company that has exited its psychedelics business and is seeking new opportunities. The news flow provides context on its strategic decisions, asset sales, governance changes, and financing activities.
Earlier announcements describe Wesana Health’s work on SANA-013, a lead drug development candidate for Major Depressive Disorder and related indications, including preclinical animal study results and feedback from a pre-IND meeting with the U.S. Food and Drug Administration. Other releases outline the company’s former care delivery assets, such as clinic management operations in the greater Chicago area, a clinical software platform, and a professional community focused on the clinical use of psychedelics.
Subsequent news highlights strategic reviews and completed transactions, including the sale of clinic management services organization assets and the sale of SANA-013 intellectual property and related assets to another life sciences company. These items are presented alongside information on private placements, short-term financing, and efforts to streamline operations and reduce expenses.
More recent communications note changes to the board of directors and state that Wesana Health discontinued its psychedelics business and disposed of the related assets in 2023, and is now looking for new business opportunities. Readers following WSNAF news can use this page to review historical announcements about its drug development activities, asset divestitures, governance updates, and capital markets transactions.
Wesana Health Holdings announced positive results from an animal study examining the effects of psilocybin combined with imipramine in treating depression. The study showed that administering imipramine three weeks after a psilocybin dose resulted in a 39% improvement in depressive behaviors, while a second dose four weeks later led to a 45% reduction. This suggests potential for enhanced treatment options for depression. Additionally, Wesana has engaged MDM Worldwide for investor relations services at $8,000 per month for six months, plus stock compensation.
Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF) announced progress in the clinical development of SANA-013, a novel therapy targeting Traumatic Brain Injury (TBI)-related major depressive disorder. Following a pre-Investigational New Drug (IND) meeting, the FDA provided positive feedback on requirements to advance to clinical studies. Wesana plans to initiate in-human trials in late 2022, leveraging a new psilocybin and cannabidiol therapy protocol aimed at delivering sustained therapeutic effects. The company aims to meet FDA guidelines in its ongoing development efforts.
Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF) announced the construction of its third mental health clinic in Naperville, IL, expected to open in Spring 2022. The 3,000 square-foot facility will offer innovative psychiatric care, including ketamine therapy and Deep Transcranial Magnetic Stimulation for conditions like Major Depression. The investment for the clinic's build-out is approximately USD $250,000. Additionally, Wesana has entered into a sixty-day investor relations agreement with Future Money Trends LLC for USD $500,000 to enhance public awareness.
Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF) has appointed Meghna A. Gaeta as Chief Marketing Officer to lead its marketing strategy. Gaeta, with over 18 years of experience in healthcare and technology marketing, aims to bridge the gap between patients and providers, enhancing Wesana's position in mental health care delivery. The company has also engaged North Equities for investor communications, paying $70,000 in restricted stock units. These strategic moves are expected to bolster Wesana's clinical network and market presence.
Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF) announces positive results from an animal study on its innovative depression treatment protocol. The study showed that a single high dose of psilocybin leads to rapid improvements in depressive behaviors for up to 14 days. Following this, a maintenance regimen combining microdoses of psilocybin and cannabidiol resulted in an additional 64% reduction in depressive behaviors. This protocol is being evaluated for major depressive disorder associated with traumatic brain injury, marking a significant step forward in mental health treatment.
Wesana Health Holdings (OTCQB: WSNAF) recently announced key updates regarding its Care Development and Care Delivery strategies. The FDA has granted a pre-IND meeting for its drug candidate SANA-013 aimed at treating TBI-related major depressive disorder, scheduled for March 11, 2022. Wesana Clinics reported record performance in Q4, with significant increases in patient visits and telemedicine use. A new flagship clinic is set to open in late Q1 2022, and the company is implementing a restructuring program expected to reduce overhead by $1.1M to enhance operational efficiency.
Wesana Health Holdings (CSE: WESA; OTCQB: WSNAF) announced a pre-IND meeting with the U.S. FDA for its therapy SANA-013 targeting Traumatic Brain Injury (TBI) related major depressive disorder (MDD). Scheduled for March 11, 2022, this meeting will provide feedback on the company's toxicology program before initiating a Phase I clinical trial, expected late 2022. CEO Daniel Carcillo emphasized the urgency for effective treatments, noting existing therapies achieve only a 30-40% success rate.
Wesana aims to enhance neuroplasticity and neurogenesis using a combination of psilocybin and CBD.
Wesana Health announced positive results from a commercial viability analysis by the Boston Consulting Group (BCG), confirming the potential for MDMA-assisted therapy in treating traumatic brain injury (TBI). The findings bolster partnership discussions with the Multidisciplinary Association for Psychedelic Studies (MAPS). CEO Daniel Carcillo highlighted the report's impact on the development of therapies for TBI, an issue costing the US ~$76.5 billion annually. The collaboration aims to expedite research timelines and enhance access to this promising treatment.
Wesana Health Holdings (CSE: WESA; OTCQB: WSNAF) has filed a Patent Cooperation Treaty (PCT) application for protocols and delivery methods utilizing psilocybin-assisted psychotherapy to treat neurological conditions, including traumatic brain injury (TBI) symptoms like depression and anxiety. The application aims for protection in major global markets. CEO Daniel Carcillo expressed excitement over this step towards innovative therapies, while Chief Scientific Officer Dr. Mark Wingertzahn noted its advancement in their proprietary development portfolio.
Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF) announced its Q3 2021 results, highlighting a cash balance of US$11,266,187 and total assets of US$36,284,015. The company completed the acquisition of PsyTech, launching a new Care Delivery segment, and pledged US$1.5 million to MAPS for research on MDMA therapy for Traumatic Brain Injury (TBI). Wesana is positioned for growth with an expansion into clinical settings and was included in the AdvisorShares Psychedelics ETF.